MetLife Investment Management’s Vor Biopharma VOR Stock Holding History

MetLife Investment Management’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,060	Closed	-$65.5K	–	2985
2023 Q2	$65.5K	Buy	+1,060	New	+$96.8K	﹤0.01%	2867
2022 Q1	–	Sell	-413	Closed	-$96.1K	–	2776
2021 Q4	$96.1K	Hold	413	–	–	﹤0.01%	2417
2021 Q3	$130K	Buy	+413	New	+$123K	﹤0.01%	2325
2021 Q2	–	Sell	-276	Closed	-$238K	–	2492
2021 Q1	$238K	Buy	+276	New	+$234K	﹤0.01%	1961

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

MetLife Investment Management's VOR Position: Q3 2023 in Review

MetLife Investment Management sold out of Vor Biopharma (VOR) in Q3 2023, closing a stake of 1,060 shares — an estimated $65.5K sold.

MetLife Investment Management first reported a position in VOR in Q1 2021 and held it in 4 quarters. The position peaked at $238K in Q1 2021. 59 funds tracked by Wall St. Rank hold VOR as of Q3 2023.

MetLife Investment Management reported no remaining Vor Biopharma position as of Q3 2023 after selling out during the quarter.
MetLife Investment Management sold 1,060 Vor Biopharma shares in Q3 2023, an estimated $65.5K.
MetLife Investment Management first reported a position in Vor Biopharma in Q1 2021 and held it in 4 quarters.
MetLife Investment Management's Vor Biopharma position peaked at $238K in Q1 2021.
59 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.